U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H30N5O10P.C4H4O4
Molecular Weight 635.5149
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TENOFOVIR DISOPROXIL FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C

InChI

InChIKey=VCMJCVGFSROFHV-WZGZYPNHSA-N
InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C19H30N5O10P
Molecular Weight 519.4428
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310

CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO).

CNS Activity

Originator

Chimerix
20
Curator's Comment: reference retrieved from http://www.sciencedirect.com/science/article/pii/S2211383512001402

Approval Year

2001
194
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 58.0 µM [Kd]
Inhibitor
8297
 3.3 nM [EC50]
Inhibitor
8297
 3.5 nM [EC50]
Inhibitor
8297
 0.49 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
VIREAD

Approved Use

Tenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections

Launch Date

1.32675836E12
Primary
Approved
8429
VIREAD

Approved Use

Tenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections

Launch Date

1.32675836E12
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0205
http://www.3bsc.com/index/pro_info.php?id=19561
AA Blocks
AA001EJQ
http://www.aablocks.com/goods/Goods/detail?id=AA001EJQ
AEchem Scientific Corp., USA
AE1-016163
http://www.aechemsc.com/info_products/AE1-016163.php
AHH Chemical co.,ltd
API-1191
http://www.ahhchemical.com/product/API-1191.html
AK Scientific, Inc. (AKSCI)
J90012
http://www.aksci.com/item_detail.php?cat=J90012
Aaron Chemicals
AR001FBI
http://www.aaronchem.com/147127-20-6
AbMole Bioscience
M5051
http://www.abmole.com/products/tenofovir.html
Acorn PharmaTech
ACN-029240
http://www.acornpharmatech.com/
Active Biopharma
ABP000917
http://www.activebiopharma.com/147127-20-6
Adooq BioScience
A10908
https://www.adooq.com/tenofovir-viread.html
Alsachim
1763
http://www.alsachim.com/product-C2530-glo.bal-view.html
Angene
AGN-PC-0PZUPY
http://www.angenechemical.com/productshow/AGN-PC-0PZUPY.html
ApexBio Technology
A5275
http://www.apexbt.com/tenofovir.html
AstaTech, Inc.
34244
http://www.astatechinc.com/CPSResult.php?CRNO=35657
Aurum Pharmatech LLC
S-2389
http://www.Aurumpharmatech.com/Product/ProductDetails/S_2389
AvaChem Scientific
2678
http://www.avachem.com/productSearch.asp?2678
Axon MedChem
3157
https://www.axonmedchem.com/product/3157
BLD Pharm
BD01204701
http://www.bldpharm.com/products/107021-12-5.html
BLD Pharm
BD18435
http://www.bldpharm.com/products/147127-20-6.html
BioCrick
BCC2500
http://www.biocrick.com/Tenofovir-BCC2500.html
BioSynth
Q-201787
https://www.biosynth.com/en/products/life-science/enzyme-substrates-reagents/products/Q-201787.html
Boerchem
BC208449
http://www.boerchem.com/?product_35256.html
CSNpharm
CSN12559
https://www.csnpharm.com/products/tenofovir.html
Capot Chemical
9452
http://www.capotchem.com/en/9452.htm
Capot Chemical
PubChem9452
http://www.capotchem.com/en/9452.htm
Chem Scene
CS-1609
http://www.chemscene.com/147127-20-6.html
ChemMol
1032196
http://www.chemmol.com/chemmol/1032196.html
ChemMol
30108887
http://www.chemmol.com/chemmol/30108887.html
ChemMol
44003255
http://www.chemmol.com/chemmol/44003255.html
ChemMol
97900713
http://www.chemmol.com/chemmol/97900713.html
ChemReagents
80014913
http://www.chemreagents.com/Product/Product.asp?ProductID=80014913
Chemenu
CM110444
http://www.chemenu.com/products/CM110444
Chemspace
CSSB00016987604
https://chem-space.com/CSSB00016987604
Chiralblock Biosciences
CB10985
http://www.chiralblock.com/products/147127-20-6.html
Matrix Scientific
74030
https://www.matrixscientific.com/074030.html
MedChem Express
HY-13910
https://www.medchemexpress.com/tenofovir.html
OChem
5252
http://www.ocheminc.com/index.php?act=psearch&pid=127T206
Oakwood
77792
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=62966&ExtHyperLink=1
Selleck Chemicals
S1401
http://www.selleckchem.com/products/Tenofovir.html
Sigma-Aldrich
SML1795_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/sml1795?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S544915
http://www.smolecule.com/products/s544915
Smolecule
S752291
https://www.smolecule.com/products/s752291
TCI (Tokyo Chemical Industry)
T3006
http://www.tcichemicals.com/eshop/en/us/commodity/T3006/index.html
THE BioTek
bt-284194
https://www.thebiotek.com/product/inhibitors/bt-284194
THE BioTek
bt-293647
https://www.thebiotek.com/product/others/bt-293647
Tocris
3666
https://www.tocris.com/products/tenofovir_3666
Yuhao Chemical
A0500092
http://www.chemyuhao.com/147127-20-6.html
abcr GmbH
AB437841
http://www.abcr.com/shop/en/AB437841
eNovation Chemicals
D320167
http://www.enovationchem.com/productDetails.asp?productID=D320167
eNovation Chemicals
D275770
https://www.enovationchem.com/ProductDetails.asp?ProductID=D275770
iChemical
EBD47973
http://www.ichemical.com/products/147127-20-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.
1993 Feb
Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine.
1998 Oct 16
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
2010 Jul
Patents

Patents

20080103115
20
20110021464
20
EP2440560
20
JP2011506374A
20

Sample Use Guides

In Vivo Use Guide
The recommended dose of Ictady (tenofovir disoproxil succinate) for the treatment of HIV or for the treatment of chronic hepatitis B is 245 mg (one tablet) once daily taken orally with food.
Route of Administration: Oral
In Vitro Use Guide
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA known as tenofovir) exerts antiretrovirus activity in MT-4 cells infected with HIV-1 and HIV-2 with EC50 values of 5.9 and 4.9 uM, respectively
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:28:20 UTC 2023
Edited
by admin
on Fri Dec 15 15:28:20 UTC 2023
Record UNII
OTT9J7900I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TENOFOVIR DISOPROXIL FUMARATE
EMA EPAR   HSDB   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN  
Official Name English
TENOFOVIR DISOPROXIL FUMARATE [JAN]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF ODEFSEY
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [HSDB]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF TEMIXYS
Common Name English
GS-4331-05
Code English
TENOFOVIR DISOPROXIL FUMARATE [USAN]
Common Name English
9-((R)-2-((BIS(((ISOPROPOXYCARBONYL)OXY)-METHOXY)PHOSPHINYL)METHOXY)PROPYL)ADENINE FUMARATE (1:1)
Common Name English
TENOFOVIR DF
Common Name English
TENOFOVIR (AS DISOPROXIL FUMARATE)
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [VANDF]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF STRIBILD
Brand Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF TRUVADA
Brand Name English
GSK548470
Code English
TENOFOVIR DISOPROXIL FUMARATE [WHO-IP]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF EVIPLERA
Brand Name English
Tenofovir disoproxil fumarate [WHO-DD]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [MI]
Common Name English
TENOFOVIRI DISOPROXILI FUMARAS [WHO-IP LATIN]
Common Name English
EVIPLERA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
TENOFOVIR DISOPROXIL FUMARATE [EMA EPAR]
Common Name English
ATRIPLA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Common Name English
TEMIXYS COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Common Name English
VIREAD
Brand Name English
TENOFOVIR DISOPROXIL FUMARATE [ORANGE BOOK]
Common Name English
GSK-548470
Code English
ODEFSEY COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [MART.]
Common Name English
STRIBILD COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
PMPA-PRODRUG
Code English
TENOFOVIR DISOPROXIL FUMARATE [USP-RS]
Common Name English
Bis(hydroxymethyl) [[(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1)
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF ATRIPLA
Common Name English
DELSTRIGO COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
GS-4331-05-
Code English
PMPA PRODRUG
Code English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT DELSTRIGO
Brand Name English
TRUVADA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
(R)-5-((2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-2,4,6,8-TETRAOXA-5-PHOSPHANONANEDIOIC ACID, BIS(1-METHYLETHYL) ESTER, 5-OXIDE, (E)-2-BUTENEDIOATE (1:1)
Common Name English
VIREA
Brand Name English
TDF
Common Name English
9-((R)-2-((BIS(((ISOPROPOXYCARBONYL)OXY)METHOXY)PHOSPHINYL)METHOXY)PROPYL)ADENINE FUMARATE (1:1)
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS VIREAD (AUTHORIZED: HEPTATITS B, CHRONIC)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
NCI_THESAURUS C97452
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EU-Orphan Drug EU/3/14/1419
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS EVIPLERA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
FDA ORPHAN DRUG 538416
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
FDA ORPHAN DRUG 559316
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS TRUVADA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS VIREAD (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
Code System Code Type Description
CAS
202138-50-9
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
MERCK INDEX
m10559
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY Merck Index
CHEBI
63717
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
RXCUI
322248
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID5050426
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
TENOFOVIR DISOPROXIL FUMARATE
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY Description: White to almost-white, crystalline powder. Solubility: Slightly soluble in water, soluble in methanol, very slightly soluble in dichloromethane. Category: Antiretroviral (Nucleotide Reverse Transcriptase Inhibitor). Storage: Tenofovir disoproxil fumarate should be kept in a tightly closed container, protected from light and stored at a temperature between 2?8 ?C. Additional information: Tenofovir disoproxil fumarate may exhibit polymorphism. Definition: Tenofovir disoproxil fumarate contains not less than 98.5% and not more than 101.0% of tenofovir disoproxil fumarate(C19H30N5O10P,C4H4O4), calculated with reference to the anhydrous substance. Manufacture: The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 5 ppm for the mutagenic impurity 9-propenyladenine (impurity K), which may be a synthesis related substance, using a suitable method; ? a limit of not more than 1.0% for the tenofovir disoproxil (S)-enantiomer (impurity G) using a suitable chiral chromatographic method.
DAILYMED
OTT9J7900I
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
NCI_THESAURUS
C47747
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
EVMPD
SUB12607MIG
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
SMS_ID
100000092141
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
PUBCHEM
6398764
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
CHEBI
63718
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
USAN
KK-89
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
DRUG BANK
DBSALT000172
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
RS_ITEM_NUM
1643656
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
FDA UNII
OTT9J7900I
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL1538
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
HSDB
7165
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
Related Record Type Details
Structure of TENOFOVIR DISOPROXIL
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of TENOFOVIR DISOPROXIL DIMER
IMPURITY -> PARENT
Amount Not Specified
Structure of ETHYL 1-METHYLETHYL (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-5-OXO-2,4,6,8-TETRAOXA-5-.LAMBDA.5-PHOSPHANONANEDIOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of TENOFOVIR MONO POC DIMER
IMPURITY -> PARENT
Structure of TENOFOVIR ISOPROXIL MONOESTER
IMPURITY -> PARENT
In the chromatogram obtained with solution (1) the area of any peak due to tenofovir monosoproxil (impurity A) is not greater than twice the area of the principal peak obtained with solution (2) (1.0%).
Structure of TENOFOVIR DISOPROXIL (S)-ENANTIOMER
IMPURITY -> PARENT
The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 1.0% for the tenofovir disoproxil (S)-enantiomer (impurity G) using a suitable chiral chromatographic method.
Structure of (R)-ISOPROPYL (9-(2-((BIS(((ISOPROPOXYCARBONYL)OXY)METHOXY)PHOSPHORYL)METHOXY)PROPYL)-9H-PURIN-6-YL)CARBAMATE
IMPURITY -> PARENT
Structure of (1-METHYLETHYL) (8R)-5-HYDROXY-8-METHYL-9-(6-(((1-METHYLETHOXY)CARBONYL)AMINO)-9H-PURIN-9-YL)-5-OXO-2,4,7-TRIOXA-5-.LAMBDA.5-PHOSPHANONANOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of 1-METHYLETHYL PROPYL (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-5-OXO-2,4,6,8-TETRAOXA-5-.LAMBDA.5-PHOSPHANONANEDIOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of Mono-POC Isopropyl Tenofovir fumarate
IMPURITY -> PARENT
Structure of TENOFOVIR MONOSOPROXIL DIMER
IMPURITY -> PARENT
Amount Not Specified
Structure of Mono-POC Isopropyl Tenofovir
IMPURITY -> PARENT
Amount Not Specified
Structure of (1-METHYLETHYL) (5RS,8R)-9-(6-AMINO-9H-PURIN-9-YL)-5-METHOXY-8-METHYL-5-OXO-2,4,7-TRIOXA-5-.LAMBDA.5-PHOSPHANONANOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of (1-METHYLETHYL) (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-10-METHYL-5,9-DIOXO-2,4,6,8-TETRAOXA-10-AZA-5-.LAMBDA.5-PHOSPHAUNDECANOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of 9-(1E)-1-Propen-1-yl-9H-purin-6-amine
IMPURITY -> PARENT
The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 5 ppm for the mutagenic impurity 9-propenyladenine (impurity K), which may be a synthesis related substance, using a suitable method.
Structure of TENOFOVIR DI AND MONOSOPROXIL HETERODIMER
IMPURITY -> PARENT
Amount Not Specified
Structure of TENOFOVIR ANHYDROUS
IMPURITY -> PARENT
Structure of METHYL (1-METHYLETHYL) (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-5-OXO-2,4,6,8-TETRAOXA-5-.LAMBDA.5-PHOSPHANONANEDIOATE
IMPURITY -> PARENT
Amount Not Specified
Related Record Type Details
Structure of TENOFOVIR ANHYDROUS
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966